Search Results | Blood | American Society of Hematology

1-20 of 43

2 3

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Blood (2023) 141 (3): 219–230.

DOI: https://doi.org/10.1182/blood.2022015526

Published: 2023

Includes: Supplemental data

Journal Articles

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Blood (2022) 140 (Supplement 1): 13264–13266.

DOI: https://doi.org/10.1182/blood-2022-159637

Published: 2022

Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Blood (2022) 140 (Supplement 1): 4646–4648.

DOI: https://doi.org/10.1182/blood-2022-158563

Published: 2022

Journal Articles

Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

Nathan Becker, Enze Liu, Parvathi Sudha, Aneta Mikulasova, Travis S Johnson, Attaya Suvannasankha, Mohammad Issam Abu Zaid, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9970–9971.

DOI: https://doi.org/10.1182/blood-2022-157086

Published: 2022

Journal Articles

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Mohammad Issam Abu Zaid, Parvathi Sudha, Travis S Johnson, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Attaya Suvannasankha, Sherif S Farag, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9919–9920.

DOI: https://doi.org/10.1182/blood-2022-167619

Published: 2022

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

DOI: https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood (2022) 140 (Supplement 1): 10140–10141.

DOI: https://doi.org/10.1182/blood-2022-159969

Published: 2022

Journal Articles

Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease

Attaya Suvannasankha, Colin D. Crean, David Halladay, David G. Roodman, John Chirgwin

Blood (2022) 140 (Supplement 1): 7104–7105.

DOI: https://doi.org/10.1182/blood-2022-171069

Published: 2022

Journal Articles

Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma

Zachary S Meyer, Mohamed Manaa, Yan Han, Magdalena Czader, Attaya Suvannasankha, Rafat Abonour, Sherif S Farag, Melissa Stanley, Mohammad Issam Abu Zaid

Blood (2021) 138 (Supplement 1): 4903.

DOI: https://doi.org/10.1182/blood-2021-149595

Published: 2021

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

DOI: https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD

Blood (2017) 130 (Supplement 1): 1824.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1826.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826

Published: 2017

Journal Articles

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo, Jianping Wang, Kerri Nottage, Christopher Chiu, Nushmia Z. Khokhar, Tahamtan Ahmadi, Sagar Lonial

Blood (2017) 130 (8): 974–981.

DOI: https://doi.org/10.1182/blood-2017-05-785246

Published: 2017

Includes: Supplemental data

Journal Articles

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

Attaya Suvannasankha, MD, Colin D Crean, Douglas R Tompkins, Jesus Delgado-Calle, PhD, Teresita M Bellido, PhD, G. David Roodman, MD PhD, John M Chirgwin, PhD

Blood (2016) 128 (22): 4439.

DOI: https://doi.org/10.1182/blood.V128.22.4439.4439

Published: 2016

Journal Articles

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

Attaya Suvannasankha, MD, Sherif Farag, MD PhD, Rebecca Silbermann, MD, Mary Cangany, RN, Anita Rush-Taylor, RN, Robin O'Bryant, RN, Lisa Wood, RN, Jean Pearson, Sarah Singleton, Andrea Bradley, Sandra Althouse, Susan Perkins, PhD, Deb Estes, RN, Rafat Abonour, MD

Blood (2015) 126 (23): 3193.

DOI: https://doi.org/10.1182/blood.V126.23.3193.3193

Published: 2015

Journal Articles

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

Craig C Hofmeister, MD MPH, Jesus G. Berdeja, MD, David H. Vesole, MD PhD, Attaya Suvannasankha, MD, Tracy Parrott, Rafat Abonour, MD

Blood (2015) 126 (23): 3052.

DOI: https://doi.org/10.1182/blood.V126.23.3052.3052

Published: 2015

Journal Articles

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

Ajai Chari, MD, Sagar Lonial, MD, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Xiang Qin, Tara Masterson, Kerri Nottage, Jordan M Schecter, Tahamtan Ahmadi, Brendan Weiss, Amrita Krishnan, Suzanne Lentzsch

Blood (2015) 126 (23): 508.

DOI: https://doi.org/10.1182/blood.V126.23.508.508

Published: 2015

Journal Articles

CD166 Identifies Multiple Myeloma Cells That Preferentially Home to the Bone Marrow Microenvironment and Promote Disease Progression and Bone Lytic Disease

Linlin Xu, Christophe Machal, Hao Wu, Colin D Crean, Bradley Poteat, Angelo A. Cardoso, Helmut Hanenberg, Khalid Mohammad, Attaya Suvannasankha, Edward F Srour

Blood (2014) 124 (21): 174.

DOI: https://doi.org/10.1182/blood.V124.21.174.174

Published: 2014

Journal Articles

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Linlin Xu, Christophe Machal, Hao Wu, Bradley Poteat, Colin D. Crean, Angelo A. Cardoso, MD, PhD, John M Chirgwin, PhD, Helmut Hanenberg, MD, Khalid S. Mohammad, M.D. Ph.D., Attaya Suvannasankha, MD, Edward F Srour, PhD

Blood (2013) 122 (21): 3102.

DOI: https://doi.org/10.1182/blood.V122.21.3102.3102

Published: 2013

Journal Articles

Neonatal Mouse Bone Supports Growth Of Primary Myeloma Cells Ex Vivo and Assessment Of Responses To Antimyeloma Drugs

Attaya Suvannasankha, MD, Douglas R Tompkins, MS, Kateryna Petyaykina, Colin D. Crean, Keith W Condon, PhD, G. David David Roodman, MD, PhD, John M Chirgwin, PhD

Blood (2013) 122 (21): 1893.

DOI: https://doi.org/10.1182/blood.V122.21.1893.1893

Published: 2013

2 3

NARROW

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease

Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D

Phase I/II Study of Lenalidomide and High Dose Melphalan As Preparative Regimen in Autologous Transplant in Myeloma: Report of Phase II Efficacy and Safety Data

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

CD166 Identifies Multiple Myeloma Cells That Preferentially Home to the Bone Marrow Microenvironment and Promote Disease Progression and Bone Lytic Disease

Role Of CD166 In Multiple Myeloma Cell Homing To The Bone Marrow Microenvironment and Disease Progression

Neonatal Mouse Bone Supports Growth Of Primary Myeloma Cells Ex Vivo and Assessment Of Responses To Antimyeloma Drugs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only